Trials (TAYS Cancer Centre Tampere University Hospital): Revision history

14 December 2025

• curprev 14:3214:32, 14 December 2025‎ Francine talk contribs‎ 9,840 bytes +198‎ No edit summary undo

6 December 2025

• curprev 12:4212:42, 6 December 2025‎ Lucas talk contribs‎ m 9,642 bytes +1,701‎ Update categories. undo

2 December 2025

• curprev 20:2920:29, 2 December 2025‎ Francine talk contribs‎ 7,941 bytes +7‎ No edit summary undo
• curprev 14:0014:00, 2 December 2025‎ Lucas talk contribs‎ m 7,934 bytes +1,588‎ Update categories. undo

5 November 2024

• curprev 23:5923:59, 5 November 2024‎ Victor talk contribs‎ 6,346 bytes +12‎ No edit summary undo

4 January 2024

• curprev 15:2315:23, 4 January 2024‎ Francine talk contribs‎ 6,334 bytes +133‎ No edit summary undo

1 December 2023

• curprev 21:1721:17, 1 December 2023‎ Francine talk contribs‎ 6,201 bytes +6,201‎ Created page with "{{forpatients}} {{forproviders}} {{forresearchers}} Go back to TAYS Cancer Centre Tampere University Hospital page '''NCTID''': NCT04736706 '''Title''': A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012) '''Study Summary''': The goal of..."